Relapsed and/or Refractory Multiple Myeloma research hub

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM

This study is testing a new medicine, Alnuctamab, for people in the UK with multiple myeloma whose cancer has come back or isn't responding to other treatments. Researchers want to see if Alnuctamab works better and is safer than current treatments, aiming to stop the cancer from growing for longer.